Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cellibre

Explore full profile

Turns cells into specialized, sustainable factories for the manufacture of globally significant products at scale

San Diego, United StatesFounded 2017Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2021
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Cellibre and the history behind them.

About Cellibre

Cellibre operates in the biomanufacturing sector, focusing on the sustainable production of cannabinoid ingredients through advanced cellular engineering. The company serves pharmaceutical, wellness, and consumer goods industries by providing high-quality, cost-effective cannabinoid compounds. Cellibre leverages fermentation technology to move production from traditional agricultural methods to controlled environments, enhancing efficiency and reducing environmental impact. The business model revolves around licensing its proprietary technology and selling the produced cannabinoids to various clients. Revenue is generated through technology licensing fees and direct sales of cannabinoid products.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
San Diego, United States
Employees
26
Open positions
1
Dealroom signal
63.6/100
Industry
Health, Food
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Fermentation, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Latest news

Press, funding announcements and product moves mentioning Cellibre.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC Oct 2025 $0 Symrise
GRANTOther financing Jun 2024 $2M National Institutes of Health
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Cellibre website traffic

Latest recorded traffic for Cellibre is 1.1K monthly website visits, up 243.8% over the last three months. Cellibre's team grew 4% over the past year.

Latest monthly visits1.1K 3-month web change+243.8% 1-year team growth+4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Pioneer BiolabsB2B biomanufacturing company leveraging its proprietary genomic screening platform to engineer and optimize microbial cells for protein production Provo, United States Operational 4
Phyx44Creating nature-identical, cell derived alternatives to dairy products Bengaluru, India Operational
TurtleTreeCreating real milk in full composition, functionality, and taste using cell-based tech Sacramento, United States Operational
Amai ProteinsProduces protein ingredients for food and beverage: the first focus is sweet 'designer' proteins as sugar substitutes Rehovot, Israel Operational
AplantexAplantex uses proprietary technology based on "omics" to produce a large catalog of high-value plant-based active ingredients for various markets Montreal, Canada Operational
Canadian Pacifico Seaweeds Ltd.Provides consultation and farmer support throughout all phases of farming development from site selection and design to deployment and maintenance Surrey, Canada Operational
Refine BiologyBiotechnology firm that engages in research, development, and manufacturing of natural food ingredients Dongcheng District, China Operational
GenbiomaA biotechnology platform based on healthcare research for creating cutting-edge food products ready to market Noáin (Valle de Elorz)/Noain (Elortzibar), Spain Operational
Showing 8 of the closest matchesCompare every metric →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A7 investors entered at this stage

  • Merida Capital Partners
  • Scott Gordon
  • Delta Emerald Ventures
  • Entourage Effect Capital
  • L2 Ventures
  • Flatiron Venture Partners
  • Symrise

Other known investors5 additional known investors

  • Alumni Ventures
  • Archytas Ventures
  • Arcview Ventures
  • Beresford Ventures
  • Towerview Ventures
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cellibre on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cellibre’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.